肌层浸润性膀胱癌的精准新辅助化疗进展研究

王坤; 段鑫鑫; 姚欣

doi:10.3969/j.issn.1000-8179.2020.22.706

肌层浸润性膀胱癌的精准新辅助化疗进展研究

doi: 10.3969/j.issn.1000-8179.2020.22.706

天津医科大学肿瘤医院泌尿肿瘤科, 国家肿瘤临床医学研究中心, 天津市肿瘤防治重点实验室, 天津市恶性肿瘤临床医学研究中心(天津市 300060)

基金项目:

国家自然科学基金青年科学基金项目 81602245

详细信息

作者简介:
王坤专业方向为泌尿肿瘤的临床诊疗及肿瘤基因治疗的基础研究等。E-mail:wangkun8312@163.com

通讯作者:
姚欣 yaoxin@tjmuch.com

计量
- 文章访问数: 233
- HTML全文浏览量: 47
- PDF下载量: 29
- 被引次数: 0
出版历程
- 收稿日期: 2020-06-17
- 刊出日期: 2020-12-26

Advances in precision neoadjuvant chemotherapy for muscle-invasive bladder cancer

Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

Funds:

the National Natural Science Foundation of China Youth Science Foundation Project 81602245

More Information

Corresponding author: Xin Yao; E-mail: yaoxin@tjmuch.com

摘要

摘要: 膀胱癌是泌尿系统最常见的恶性肿瘤，其中肌层浸润性膀胱癌（muscle-invasive bladder cancer，MIBC）占25%~30%。MIBC的标准治疗方式为新辅助化疗（neoadjuvant chemotherapy，NAC）+膀胱癌根治术，而只行根治术的5年生存率低。NAC虽可杀灭微转移癌病灶，使肿瘤降期，提高患者的总生存率，仅化疗后病理降期可使患者生存获益，无效的化疗可能会延误患者治疗，如何精准选择行NAC的患者是临床面临的难题。本文将对MIBC的NAC的应用现状及疗效预测进行综述。
- 肌层浸润性膀胱癌 /
- 新辅助化疗 /
- 精准治疗 /
- 分子标志物
Abstract: Urinary bladder cancer is the most common malignant tumor of the urinary system. Muscle-invasive bladder cancer(MIBC) accounts for 25%-30% of bladder cancer cases. The 5-year overall survival rate in patients with MIBC treated with radical cystectomy alone is low. Neoadjuvant chemotherapy(NAC) combined with radical cystectomy is the standard treatment for localized MIBC. NAC can destroy micrometastasis foci, downstage tumors, and improve the overall survival of patients; however, NAC is only effective in pT≤ T1 patients after chemotherapy. Ineffective chemotherapy may delay patients treatment. How to accurately select patients for NAC is a serious conundrum for clinical workers. This article will review the application status and efficacy prediction of MIBC's NAC.
- muscle-invasive bladder cancer (MIBC) /
- neoadjuvant chemotherapy (NAC) /
- precision therapy /
- molecular markers

HTML全文

参考文献(24)

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. doi: 10.3322/caac.21551
[2]	Hermans TJN, Voskuilen CS, van der Heijden MS, et al. Neoadjuvant treatment for muscle-invasive bladder cancer:The past, the present, and the future[J]. Urol Oncol, 2018, 36(9):413-422. doi: 10.1016/j.urolonc.2017.10.014
[3]	Von Der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer:results of a large, randomized, multinational, multicenter, phase Ⅲ study[J]. J Clin Oncol, 2000, 18(17):3068-3077. doi: 10.1200/JCO.2000.18.17.3068
[4]	Griffiths G, Hall R, Sylvester R, et al. International phase Ⅲ trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer:long-term results of the BA0630894 trial[J]. J Clin Oncol, 2011, 29(16):2171-2177. doi: 10.1200/JCO.2010.32.3139
[5]	Advanced bladder cancer Meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer:a systematic review and meta-analysis[J]. Lancet, 2003, 361(9373):1927-1934. doi: 10.1016/S0140-6736(03)13580-5
[6]	Apolo AB, Kim JW, Bochner BH, et al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States[J]. Urol Oncol, 2014, 32(5):637-644. doi: 10.1016/j.urolonc.2013.12.012
[7]	Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscleinvasive bladder cancer:a systematic review and two-step metaanalysis[J]. Oncologist, 2016, 21(6):708-715. doi: 10.1634/theoncologist.2015-0440
[8]	Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer:pathologic, radiologic, and biomarker correlates[J]. J Clin Oncol, 2014, 32(18):1889-1894. doi: 10.1200/JCO.2013.52.4785
[9]	Peyton CC, Tang D, Reich RR, et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer[J]. JAMA Oncol, 2018, 4(11):1535-1542. doi: 10.1001/jamaoncol.2018.3542
[10]	Galsky MD, Stensland K, Sfakianos JP, et al. Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement[J]. J Clin Oncol, 2016, 34(22):2627-2635. doi: 10.1200/JCO.2016.67.5033
[11]	Pietzak EJ, Zabor EC, Bagrodia A, et al. Genomic differences between "primary" and "secondary" muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy[J]. Eur Urol, 2019, 75(2):231-239. doi: 10.1016/j.eururo.2018.09.002
[12]	Liu D, Plimack ER, Hoffman-Censits J, et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma[J]. JAMA Oncol, 2016, 2(8):1094-1096. doi: 10.1001/jamaoncol.2016.1056
[13]	Groenendijk FH, de Jong J, Fransen van de Putte EE, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy[J]. Eur Urol, 2016, 69(3):384-388. doi: 10.1016/j.eururo.2015.01.014
[14]	Yang Z, Zhang R, Ge Y, et al. Somatic FGFR3 mutations distinguish a subgroup of muscle-invasive bladder cancers with response to neoadjuvant chemotherapy[J]. EBio Medicine, 2018, 35:198-203. http://www.sciencedirect.com/science/article/pii/s2352396418302184
[15]	Lotan Y, Woldu SL, Sanli O, et al. Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscleinvasive bladder cancer[J]. BJU Int, 2018, 122(3):434-440. doi: 10.1111/bju.14220
[16]	Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer[J]. Eur Urol, 2015, 68(6):959-967. doi: 10.1016/j.eururo.2015.07.009
[17]	Burgess EF, Livasy C, Trufan S, et al. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy[J]. Urol Oncol, 2019, 37(12):900-906. doi: 10.1016/j.urolonc.2019.09.009
[18]	Waingankar N, Jia R, Marqueen KE, et al. The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer[J]. Urol Oncol, 2019, 37(9):572.
[19]	Sjödahl G, Lauss M, Lövgren K, et al. A molecular taxonomy for urothelial carcinoma[J]. Clin Cancer Res, 2012, 18(12):3377-3386. doi: 10.1158/1078-0432.CCR-12-0077-T
[20]	Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of highgrade bladder cancer reflect the hallmarks of breast cancer biology[J]. Proc Natl Acad Sci U S A, 2014, 111(8):3110-3115. doi: 10.1073/pnas.1318376111
[21]	Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy[J]. Cancer Cell, 2014, 25(2):152-165. doi: 10.1016/j.ccr.2014.01.009
[22]	Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer[J]. Cell, 2017, 171(3):540-556. doi: 10.1016/j.cell.2017.09.007
[23]	Seiler R, Ashab HAD, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy[J]. Eur Urol, 2017, 72(4):544-554. doi: 10.1016/j.eururo.2017.03.030
[24]	Seiler R, Gibb EA, Wang NQ, et al. Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer[J]. Clin Cancer Res, 2019, 25(16):5082-5093. doi: 10.1158/1078-0432.CCR-18-1106